{
    "clinical_study": {
        "@rank": "144504", 
        "arm_group": [
            {
                "arm_group_label": "LF-PB 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "2 IM injections = placebo + 10 mg"
            }, 
            {
                "arm_group_label": "LF-PB 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "2 IM injections = placebo + 20 mg"
            }, 
            {
                "arm_group_label": "LF-PB 30 mg", 
                "arm_group_type": "Experimental", 
                "description": "2 IM injections = 10 mg + 20 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 IM injections of placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase II, multicenter, double-blind, double-dummy, parallel-group,\n      placebo-controlled, study to evaluate LF-PB versus placebo in female patients with brest\n      cancer who are undergoing breast surgery with axillary lymphnode dissection.\n\n      Recruited patients will be randomly assigned to one of the following treatment groups:\n      Placebo, LF-PB 10 mg, LF-PB 20 mg and LF-PB 30 mg.\n\n      Mode of administration is single intramuscular (IM) injection so the treatments arms are as\n      follows:\n\n      Placebo:  2 injections of placebo LF-PB 10 mg:  2 injections = placebo + 10 mg LF-PB 20 mg:\n      2 injections = placebo + 20 mg LF-PB 30 mg:  2 injections = 10 mg + 20 mg\n\n      The study will randomize a total of 120 patients (30 per arm) in about 10 Italian Sites."
        }, 
        "brief_title": "Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphorrhea", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female aged 18 to 80 years inclusive\n\n          2. Body mass index (BMI) \u226518 kg/m2\n\n          3. Signed informed consent form\n\n          4. Diagnosis of BC\n\n          5. Undergoing breast surgery with ALND Note:  Collagen powder or fibrin sealant are not\n             permitted.\n\n          6. Negative serum pregnancy test for women of childbearing potential Note:  Female\n             patients of child-bearing potential should be advised to use adequate contraception\n             if necessary during treatment with octreotide.\n\n          7. AST and alanine aminotransferase ALT <1.5 x the upper limit of normal\n\n          8. Ability to fully understand all study procedures and to comply with study visits\n             scheduled for the duration of the study.\n\n        Exclusion Criteria:\n\n          1. Presence of any of the following conditions:\n\n               1. Previous axillary surgery on the same armpit undergoing surgery in this study\n\n               2. Previous chemotherapy or radiotherapy within five years from study drug\n                  administration\n\n               3. Previous neoadjuvant therapy\n\n               4. Recurrent BC on the same breast undergoing surgery in this study\n\n               5. Diabetes\n\n               6. Cholelithiasis\n\n               7. Hypothyroidism. If patient is being administered Euritox/ Levothyroxine (or\n                  analogues) and levels of T3, T4 and TSH are confirmed to be within the normal\n                  ranges at screening, the patient can be enrolled in this study.\n\n               8. Hepatitis\n\n               9. Pregnant or lactating\n\n              10. Human immunodeficiency virus or hepatitis B or C by screening serology\n\n          2. History of radiotherapy on the same breast or armpit undergoing surgery in this\n             study.\n\n          3. History of anaphylaxis to study drug\n\n          4. Ascertained or presumptive hypersensitivity to the active principle and/or the\n             ingredients of the study drug formulation\n\n          5. QTc interval extension at screening or baseline > 450 msec (as the mean of 3\n             consecutive readings 5 minutes apart)\n\n          6. Presence of any disease or use of concomitant medication known to increase the QT\n             interval (see Appendix 2 for a list of such compounds)\n\n          7. Clinically significant or relevant abnormal medical history, vital sign, physical\n             examination, ECG, or laboratory evaluation finding\n\n          8. Current or recurrent disease that could affect the results of the clinical or\n             laboratory assessments required for the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754285", 
            "org_study_id": "LF-PB/11/04"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LF-PB 10 mg", 
                    "LF-PB 20 mg"
                ], 
                "intervention_name": "LF-PB and Placebo", 
                "intervention_type": "Drug", 
                "other_name": "extended-release of octreotide and placebo"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }, 
            {
                "arm_group_label": "LF-PB 30 mg", 
                "intervention_name": "LF-PB", 
                "intervention_type": "Drug", 
                "other_name": "LF-PB 10 mg and LF-PB 20 mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Octreotide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 24, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Gaetano Castiglione, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Via V.E. Dabormida, 64", 
                        "country": "Italy", 
                        "state": "Catania", 
                        "zip": "95125"
                    }, 
                    "name": "Humanitas Centro Catanese di Oncologia Dipartimento di Oncologia -Chirurgia Oncologica Generale"
                }, 
                "investigator": {
                    "last_name": "Gaetano Castiglione, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Pierfrancesco Tassone, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Viale Europa-Loc. Germaneto", 
                        "country": "Italy", 
                        "state": "Catanzaro", 
                        "zip": "88100"
                    }, 
                    "name": "Fondazione per la Ricerca e la Cura dei Tumori \"Tommaso Campanella\" Unit\u00e0 Operativa Complessa CRR per il Counselling Genetico e le Terapie Innovative in Oncologia Medica"
                }, 
                "investigator": {
                    "last_name": "Pierfrancesco Tassone, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Corrado De Sanctis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Corso Spezia, 60 Torino", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "Azienda Ospedaliera OIRM Sant'Anna Dipartimento Funzionale di Oncologia - Breast Unit"
                }, 
                "investigator": {
                    "last_name": "Corrado De Sanctis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L.go Rosanna Benzi,10 Genova", 
                        "country": "Italy", 
                        "zip": "16132"
                    }, 
                    "name": "IRCCS Azienda Ospedaliero Universitaria San Martino di Genova - IST Genova Dipartimento Chirurgia Ospedaliera - Semeiotica Chirurgica e Chirurgia Senologica"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Antonio Margari, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Piazza Giulio Cesare 11 Bari", 
                        "country": "Italy", 
                        "zip": "70124"
                    }, 
                    "name": "Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari Chirurgia Generale Universitaria \"G.Marinaccio\""
                }, 
                "investigator": {
                    "last_name": "Antonio Margari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Manuela Roncella, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy", 
                        "zip": "56123"
                    }, 
                    "name": "Azienda Ospedaliero-Universitaria Di Pisa"
                }, 
                "investigator": {
                    "last_name": "Manuela Roncella, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Vittorio Altomare, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00128"
                    }, 
                    "name": "Universita` Campus Bio-medico di Roma"
                }, 
                "investigator": {
                    "last_name": "Vittorio Altomare, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roberto Murgo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "San Giovanni Rotondo", 
                        "country": "Italy", 
                        "zip": "71013"
                    }, 
                    "name": "Ospedale Casa Sollievo della Sofferenza - Istituto di Ricovero e Cura a Carattere Scientifico Opera di San Pio da Pietrelcina"
                }, 
                "investigator": {
                    "last_name": "Roberto Murgo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Riccardo Ponzone, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Strada Provinciale 142 Km 3.95- Candiolo", 
                        "country": "Italy", 
                        "zip": "10060"
                    }, 
                    "name": "Fondazione del Piemonte per l'Oncologia - IRCC Candiolo D.O. di Ginecologia Oncologica"
                }, 
                "investigator": {
                    "last_name": "Riccardo Ponzone, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dante Palli, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Via Gramsci, 14 Parma", 
                        "country": "Italy", 
                        "zip": "43126"
                    }, 
                    "name": "Azienda Ospedaliero-Universitaria di Parma Dipartimento Clinica Chirurgica e Terapia Chirurgica"
                }, 
                "investigator": {
                    "last_name": "Dante Palli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michelino De Laurentiis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Via Mariano Semmola Napoli", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Giovanni Pascale Dipartimento di Senologia - Struttura Complessa Oncologia Medica Senologica"
                }, 
                "investigator": {
                    "last_name": "Michelino De Laurentiis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Giovanni Tazzioli, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Via Pozzo 71, Modena", 
                        "country": "Italy", 
                        "zip": "41124"
                    }, 
                    "name": "Azienda Ospedaliero Universitaria Policlinico di Modena Unit\u00e0 Semplice di Senologia"
                }, 
                "investigator": {
                    "last_name": "Giovanni Tazzioli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paolo Carcoforo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Vial Aldo Moro 8, Cona-Ferrara", 
                        "country": "Italy", 
                        "zip": "44124"
                    }, 
                    "name": "Azienda Ospedaliero Universitaria di Ferrara c/o Ospedale di Cona Sezione di Clinica Chirurgica"
                }, 
                "investigator": {
                    "last_name": "Paolo Carcoforo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast Cancer", 
        "other_outcome": {
            "description": "correlation between exposure of the drug and efficacy", 
            "measure": "correlation between LF-PB exposures and efficacy after the administration of LF-PB 10 mg, 20 mg, and 30 mg", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after surgery"
        }, 
        "overall_contact": {
            "email": "p.bettica@italfarmaco.com", 
            "last_name": "Paolo Bettica, MD PhD", 
            "phone": "0039 02 6443", 
            "phone_ext": "2584"
        }, 
        "overall_official": {
            "affiliation": "Clinica Chirurgica, Azienda Ospedaliero-Universitaria Arcispedale \"S. Anna\" Ferrara", 
            "last_name": "Paolo Carcoforo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "End of lymphorrhea will be declared when the lymph volume measured by the patient is < 50 ml/day in 2 consecutive days.", 
                "measure": "effect of LF-PB 10 mg, 20 mg, and 30 mg on time to resolution of lymphorrhea;", 
                "safety_issue": "No", 
                "time_frame": "12 weeks post surgery"
            }, 
            {
                "description": "Safety and tolerability of LF-PB", 
                "measure": "number of AEs and laboratory, ECG, vital sign abnormalities of LF-PB 10 mg, 20 mg, and 30 mg", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks after surgery"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754285"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "daily volume of lymph collected from the drain", 
                "measure": "effects of LF-PB 10, 20, and 30 mg on the daily volume of lymph collected from the drain", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after surgery"
            }, 
            {
                "description": "effect of LF-PB 10, 20 and 30 mg on complications related to lymphorrhea", 
                "measure": "number of complications related to lymphorrhea", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after surgery"
            }, 
            {
                "description": "PK parameters", 
                "measure": "PK profile (Cmax, Tmax, AUC0-t and possibly AUC0-inf and T1/2) of LF-PB 10, 20 and 30 mg", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after surgery"
            }
        ], 
        "source": "Chemi S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chemi S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}